Lucentis Injection Should Be Given To Wet AMD Patients, Says NICE, UK
Editor's ChoiceMain Category: Eye Health / Blindness
Also Included In: Seniors / Aging
Article Date: 14 Dec 2007 - 0:00 PDT
| Patient / Public: | ![]() |
4.46 (13 votes) |
| Healthcare Prof: | ![]() |
5 (2 votes) |
| Article Opinions: | 1 posts |
Patients with wet age-related macular degeneration (Wet AMD) should be eligible for 14 lucentis (ranibizumab) injections per eye, says the National Institute for Health and Clinical Excellence (NICE). This is a complete reversal on its previous recommendation. The new recommendation does not include eligibility for Macugen, another injection.
* Wet age-related macular degeneration is known as Wet ARMD, or Wet AMD
According to NICE, after further economic modeling of available treatments, it decided to modify its recommendation with regard to Lucentis injections.
Wet AMD is the main cause of blindness in the United Kingdom; there are approximately 26,000 new cases annually. Today about 250,000 people are effected with wet AMD in the UK.
In Scotland both Lucentis and Macugen have been widely available on the National Health Service (NHS). Both drugs are known as ant-VEGF drugs - they target a protein that stops damage to the retina.
Initially, NICE had recommended that about 20% of patients with wet AMD would be eligible to receive Lucentis injections on the NHS. This involved patients with a particular type of wet AMD who had both eyes affected - the Lucentis would only be used on the less badly affected eye.
The new recommendation includes patients who only have one eye affected, and not only patients with a particular type of wet AMD. However, treatment on the NHS will only be given to patients after a certain amount of deterioration has passed. If more than 14 injections are needed for a particular patient, the manufacturer of Lucentis will pay for the extra ones.
NICE informs that the final guidance will be published early next year.
Ophthalmologists welcome the news. However, they would like to see Macugen added as a treatment for those who have problems with Lucentis.
-- What is Age-Related Macular Degeneration?
-- www.lucentis.com
-- www.macugen.com
-- www.nice.org.uk
Written by - Christian Nordqvist
Copyright: Medical News Today
Not to be reproduced without permission of Medical News Today
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/articles/91761.php>
APA
http://www.medicalnewstoday.com/articles/91761.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Visitor Opinions In Chronological Order (1)
Great News But ....
posted by John Peal on 14 Dec 2007 at 7:48 amThis is a welcome reversal of NICE's decision for wet AMD sufferers like my mother, but while NICE and local PCT's have dithered, her sight has got worse and worse. She had medical insurance, but that only extended to 3 injections in the first eye. Unbelievably and callously, the insurers stated that the second eye "was the same claim" and therefore ineligible. It was hard trying to explain that to my mother, who is an active 85 year old and just as dependent on her sight for quality of life as we all are.
Once her medical insurers provided no further funds she felt she had the choice of going blind or paying Ł1600 a shot for Lucentis. Hobson's choice...!
The main point of this post is to ask who should pressure Genentech, who makes the licensed drug Lucentis, into also getting Avastin licensed? Anecdotal evidence from many consultants is that it is highly effective and a fraction of the cost, but cannot be provided on the NHS because it's not licensed by NICE.
Now why would Genentech want it to be licensed if they have a monopoly of the wet AMD treatment market?? So, who should steer/push/lead/bully/shame/coerce them in that direction, and they won't go voluntarily, I'm sure? It's certainly in everyone's (NHS, insurers, individuals etc) interest that they should, but no-one seems to be asking that question. Am I missing something?
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.




